Back to Authors

Baer, Emily

0000-0002-3353-3853

Mayo Clinic

Department of Urology, Mayo Clinic, Rochester, MN 55902, USA.

Citations 1

Surfaceome Profiling of Rhabdomyosarcoma Reveals B7-H3 as a Mediator of Immune Evasion
Lavoie, Roxane R. , Gargollo, Patricio C. , Ahmed, Mohamed E. , Baer, Emily , Phelps, Doris A., Charlesworth, M. Cristine , Wang, Liguo , Houghton, Peter J. , Cheville, John C. , Granberg, Candace F. , Lucien, Fabrice , Baer, Emily , Charlesworth, Cristine M, Lucien, Fabrice , Wang, Liguo , Ahmed, Mohamed , Kim, Yohan , Madden, Benjamin J. , Dong, Haidong

Cancers | September 9, 2021 | Volume: 13 | Issue: 18 | Pages: 4528

10.3390/cancers13184528 Get It

Novel therapeutic strategies are needed for the treatment of rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children. By using a combination of cell surface proteomics and transcriptomic profiling of RMS and normal muscle, we generated a catalog of targetable cell surface proteins enriched in RMS tumors. Among the top candidates, we identified B7-H3 as the major immunoregulatory molecule expressed by RMS tumors. By using a large cohort of tissue specimens, we demonstrated that B7-H3 is expressed in a majority of RMS tumors while not detected in normal human tissues. Through a deconvolution analysis of the RMS tumor RNA-seq data, we showed that B7-H3-rich tumors are enriched in macrophages M1, NK cells, and depleted in CD8+-T cells. Furthermore, in vitro functional assays showed that B7-H3 knockout in RMS tumor cells increases T-cell mediated cytotoxicity. Altogether, our study uncovers new potential targets for the treatment of RMS and provides the first biological insights into the role of B7-H3 in RMS biology, paving the way for the development of next-generation immunotherapies.